Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (2020-04-30) (Q90693693)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (2020-04-30) |
clinical trial |
Statements
APN01-COVID-19 (English)
0 references
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (English)
0 references
April 2020
0 references
September 2020
0 references
200
0 references
35 year
0 references
80 year
0 references